Institutional Buying Put A Bottom In Marvell Technology.Why This Dip in Advanced Auto Parts May be an Opportunity.Get a free copy of the research report on Omeros (OMER).Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. 48.99% of the stock is currently owned by hedge funds and other institutional investors.
purchased a new stake in Omeros in the 2nd quarter valued at $30,000. Millennium Management LLC now owns 1,220,782 shares of the biopharmaceutical company’s stock valued at $3,357,000 after buying an additional 797,034 shares in the last quarter. Millennium Management LLC grew its holdings in Omeros by 188.1% in the 2nd quarter. Laurion Capital Management LP purchased a new stake in Omeros in the 2nd quarter valued at $49,000.
Occudo Quantitative Strategies LP now owns 145,956 shares of the biopharmaceutical company’s stock valued at $401,000 after buying an additional 104,228 shares in the last quarter. Occudo Quantitative Strategies LP grew its holdings in Omeros by 249.8% in the 2nd quarter. Jane Street Group LLC now owns 42,321 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 13,190 shares in the last quarter. Jane Street Group LLC grew its holdings in Omeros by 45.3% in the 2nd quarter. Several large investors have recently added to or reduced their stakes in the stock.
0 kommentar(er)
